Fidelity provided a $4.8m second tranche after a first close featuring KNC, Ohar Pharmaceutical, Spera Pharma, Kisco and SRD Holdings.

Japan-based cancer therapy developer J-Pharma has increased a series D round that included corporates KNC Laboratories, Kisco, Ohara Pharmaceutical, Spera Pharma and SRD Holdings to $21m.

The second tranche of the round involved ¥500m ($4.8m) from Eight Roads Ventures and F-Prime Capital Partners, both venture capital vehicles for investment and financial services group Fidelity.

The July 2020 first close included contract manufacturing firm KNC, chemicals trading firm Kisco and pharmaceutical firms Ohara, Spera and SRD Holdings.

Sansei Capital Investment, MBL…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn